(:ZSAN)

Jun 02, 2022 08:00 am ET
Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the...
May 13, 2022 04:00 pm ET
Zosano Pharma Reports First Quarter 2022 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and...
Apr 29, 2022 04:00 pm ET
Zosano Pharma Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its...
Apr 11, 2022 08:00 am ET
Zosano Pharma Announces Reverse Stock Split Effective Today
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock. The reverse stock split will become...
Mar 17, 2022 04:05 pm ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. “We are in discussions with the FDA to...
Mar 03, 2022 09:55 am ET
Thinking about buying stock in Kinross Gold, Hexo Corp, Canaan, Zosano Pharma, or VEON?
NEW YORK, March 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KGC, HEXO, CAN, ZSAN, and VEON.
Feb 25, 2022 09:55 am ET
Thinking about buying stock in Camber Energy, Palantir Technologies, Zosano Pharma, Occidental Petroleum, or Zomedica?
NEW YORK, Feb. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, PLTR, ZSAN, OXY, and ZOM.
Feb 22, 2022 09:50 am ET
Thinking about buying stock in Zosano Pharma, SoFi Technologies, Color Star Technology, Petroleo Brasileiro, or Barrick Gold?
NEW YORK, Feb. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SOFI, CSCW, PBR, and GOLD.
Feb 09, 2022 09:50 am ET
Thinking about buying stock in Zosano Pharma, Banco Bradesco, AMC Entertainment, Snap, or Teva Pharmaceutical?
NEW YORK, Feb. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, BBD, AMC, SNAP, and TEVA.
Feb 08, 2022 09:55 pm ET
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one...
Feb 08, 2022 04:10 pm ET
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of...
Jan 05, 2022 12:01 pm ET
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an In
In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms. The measurements of the vaccine should have been 10μg and 15μg, not 10 g and 15 g...
Jan 05, 2022 09:55 am ET
Thinking about buying stock in Farmmi, Zosano Pharma, Hoth Therapeutics, Reliance Global, or United States Steel?
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, ZSAN, HOTH, RELI, and X.
Jan 05, 2022 09:20 am ET
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular I
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine...
Dec 13, 2021 04:30 pm ET
Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. “We are pleased to welcome Elaine, a high caliber executive, to...
Nov 29, 2021 09:45 pm ET
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award....
Nov 17, 2021 08:00 am ET
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing Zosano’s microneedle patch system....
Nov 17, 2021 07:37 am ET
Thinking about buying stock in 17 Education & Technology, Progenity, Canoo, Vir Biotechnology, or Zosano Pharma?
NEW YORK, Nov. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YQ, PROG, GOEV, VIR, and ZSAN.
Nov 10, 2021 04:10 pm ET
Zosano Pharma Reports Third Quarter 2021 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2021, as well as business highlights. “This quarter we made significant progress...
Nov 01, 2021 11:05 am ET
Thinking about buying stock in Zosano Pharma, SoFi Technologies, Quantumscape, Nokia, or Hexo?
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SOFI, QS, NOK, and HEXO.
Oct 04, 2021 08:00 am ET
Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration (“FDA”) regarding the resubmission...
Sep 02, 2021 04:30 pm ET
Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Investment Conference...
Aug 10, 2021 04:05 pm ET
Zosano Pharma Reports Second Quarter 2021 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights. “We are pleased to have initiated the healthy...
Jul 20, 2021 08:30 am ET
Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of...
May 26, 2021 04:05 pm ET
Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was...
May 25, 2021 04:05 pm ET
Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad...
May 12, 2021 04:05 pm ET
Zosano Pharma Reports First Quarter 2021 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021, as well as business highlights. “We have gained clarity from the FDA on the...
Apr 26, 2021 08:00 am ET
Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received feedback from the U.S. Food and Drug Administration (“FDA") Division of Neurology II (the “Division”) on the protocol...
Mar 11, 2021 04:05 pm ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020, as well as business highlights. “Over this past year, we made important...
Mar 09, 2021 08:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zillow Group and Zosano Pharma and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Zillow Group, Inc. (NASDAQ: Z) and Zosano Pharma Corporation (NASDAQ: ZSAN) on behalf of long-term stockholders....
Mar 02, 2021 08:30 am ET
Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Conference...
Feb 22, 2021 08:30 am ET
Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration (“FDA") Division of Neurology II (the...
Feb 11, 2021 08:31 am ET
Thinking about buying stock in Seelos Therapeutics, Celsion Corp, Zosano Pharma, Outlook Therapeutics, or Infinity Pharmaceuticals?
NEW YORK, Feb. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEEL, CLSN, ZSAN, OTLK, and INFI.
Feb 09, 2021 07:30 am ET
Thinking about buying stock in Heat Biologics, Zosano Pharma, Glu Mobile, AzurRx BioPharma, or Abeona Therapeutics?
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTBX, ZSAN, GLUU, AZRX, and ABEO.
Feb 01, 2021 08:30 am ET
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta™, Zosano’s investigational therapy for the acute treatment of migraine formulated utilizing its...
Feb 01, 2021 08:00 am ET
Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting with the U.S. Food and Drug Administration (“FDA") Division of Neurology II (the “Division”)...
Jan 20, 2021 08:31 am ET
Thinking about buying stock in Zosano Pharma, Senseonics, Tellurian, Cinedigm, or AMC Entertainment?
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZSAN, SENS, TELL, CIDM, and AMC.
Jan 05, 2021 08:31 am ET
Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, ZSAN, MRKR, FPRX, and INUV.
Jan 04, 2021 04:05 pm ET
Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on December 30, 2020 the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA). The purpose of the Type A...
Jan 04, 2021 08:30 am ET
Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference...
Dec 28, 2020 11:59 am ET
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Zosano Pharma Corporation and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zosano Pharma Corporation (“Zosano” or “the Company”) (NASDAQ:
Dec 27, 2020 01:00 pm ET
Zhang Investor Law Reminds Investors of December 28 Deadline in Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). To join the class action,...
Dec 27, 2020 11:00 am ET
ZSAN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Zosano Pharma Corporation of Class Action and Encourages Shareholders to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Zosano securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Dec 26, 2020 10:16 am ET
DEC. 28 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The...
Dec 25, 2020 09:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Zosano Pharma Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that...
Dec 24, 2020 04:18 pm ET
ZSAN FINAL DEADLINE MONDAY: ROSEN, A LEADING LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important December 28 Deadline in Securities Class Action - ZSAN
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), of the important December 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.
Dec 22, 2020 12:00 pm ET
DEADLINE ALERT for FAF, ZSAN, BMWYY, WFC, : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 22, 2020 10:00 am ET
BMWYY & ZSAN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 22, 2020 09:00 am ET
Zosano Pharma Corporation: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Zosano Pharma Corporation (NASDAQ: ZSAN) investors that acquired shares between April 24, 2020 and June 3, 2020. Investors have until December 28, 2020...
Dec 21, 2020 09:00 pm ET
ZOSANO ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Zosano Pharma Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Zosano Pharma Corp. (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020 (the “Class Period”). Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Dec 21, 2020 01:42 pm ET
DEC. 28 INVESTOR DEADLINE-ZSAN: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The...
Dec 21, 2020 11:30 am ET
DEADLINE ALERT for BMWYY, ZSAN, and WFC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 19, 2020 05:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers.   The class action, filed in United States District Court for the Northern...
Dec 18, 2020 05:31 pm ET
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Fir
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020...
Dec 18, 2020 11:57 am ET
Zhang Investor Law Reminds Investors of December 28 Deadline in Securities Class Action Lawsuit Against  Zosano Pharma Corporation – ZSAN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). To join the class action,...
Dec 18, 2020 08:00 am ET
Zosano Pharma Corporation Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Zosano Pharma Corporation (NASDAQ: ZSAN) investors that acquired shares between February 13, 2017 and September 30, 2020. Investors have until December...
Dec 17, 2020 11:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation...
Dec 16, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Dec 16, 2020 12:30 pm ET
DEADLINE ALERT for FAF, ZSAN, BMWYY, WFC, : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 15, 2020 04:03 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Zosano Pharma Corporation Investors of Important December 28 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Cont
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020...
Dec 15, 2020 12:24 pm ET
IMPORTANT DEC. 28 DEADLINE-ZSAN: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zosano Pharma Corporation– ZSAN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The...
Dec 14, 2020 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
LOS ANGELES, Dec. 14, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period").
Dec 14, 2020 11:00 am ET
DEADLINE ALERT for BMWYY, ZSAN, WFC, and EOLS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 13, 2020 12:03 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers.   The class action, filed in United States District Court for the Northern...
Dec 12, 2020 09:00 am ET
LOOMING DEADLINE Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). To join the class action,...
Dec 10, 2020 07:56 pm ET
ROSEN, A LEADING LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important December 28 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), of the important December 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.
Dec 09, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Dec 08, 2020 12:10 pm ET
LOOMING ZSAN DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The...
Dec 08, 2020 11:00 am ET
DEADLINE ALERT for FAF, ZSAN, BMWYY, WFC, : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 07, 2020 09:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers. The class action, filed in United States District Court for the Northern...
Dec 07, 2020 11:15 am ET
DEADLINE ALERT for BMWYY, ZSAN, and WFC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 04, 2020 06:00 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Zosano Pharma Corporation Investors of Important December 28 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Cont
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020...
Dec 03, 2020 11:38 am ET
Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). To join the class action,...
Dec 03, 2020 03:40 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline - ZSAN
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers.  The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-07850, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Zosano securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), seeking to pursue claims against the Defendants
Dec 02, 2020 07:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Dec 02, 2020 12:00 pm ET
DEADLINE ALERT for FAF, ZSAN, BMWYY, WFC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 01, 2020 11:00 am ET
FAF, BMWYY & ZSAN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 01, 2020 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation...
Nov 30, 2020 10:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers.   The class action, filed in United States District Court for the Northern...
Nov 30, 2020 11:10 am ET
DEADLINE ALERT for BMWYY, ZSAN, and WFC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 28, 2020 08:00 am ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm -
NEW YORK, Nov. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), of the important December 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.
Nov 25, 2020 11:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline  – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers. The class action, filed in United States District Court for the Northern...
Nov 24, 2020 09:00 pm ET
IMPORTANT DEADLINE-ZSAN: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zosano Pharma Corporation– ZSAN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The...
Nov 24, 2020 09:00 pm ET
ROSEN, A LEADING LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ZSAN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020...
Nov 24, 2020 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against JPMorgan, First American Financial, BMW, and Zosano Pharma and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of JPMorgan Chase & Co. (NYSE: JPM), First American Financial Corporation (NYSE:...
Nov 24, 2020 10:24 am ET
ZSAN DEADLINE NOTICE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). To join the class action,...
Nov 22, 2020 12:24 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline  – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers.   The class action, filed in United States District Court for the Northern...
Nov 21, 2020 12:06 pm ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
SAN DIEGO, Nov. 21, 2020 /PRNewswire/ -- Johnson Fistel, LLP, announces that class action lawsuits have commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead
Nov 20, 2020 12:30 pm ET
DEADLINE ALERT for WRTC, GLNG, FAF, ZSAN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 19, 2020 11:45 am ET
DEADLINE ALERT for ZSAN and WFC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 18, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zosano Pharma Corporation (NASDAQ: ZSAN), Celsion Corporation (NASDAQ: CLSN),...
Nov 18, 2020 01:07 pm ET
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action – ZSAN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020...
Nov 16, 2020 11:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline  – ZSAN
Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) and certain of its officers.   The class action, filed in United States District Court for the Northern...
Nov 16, 2020 06:30 pm ET
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of the Board of Directors granted a stock option to purchase 100,000 shares of Zosano’s common stock to a new...
Nov 16, 2020 01:57 pm ET
SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zosano Pharma Corporation– ZSAN; IMPORTANT DEADLINE-ZSAN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The...
Nov 16, 2020 10:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
LOS ANGELES, Nov. 16, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period").
Nov 13, 2020 04:05 pm ET
Zosano Pharma Reports Third Quarter 2020 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020, as well as recent business updates. “Our priority focus is obtaining resolution...
Nov 13, 2020 10:29 am ET
ZSAN STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against  Zosano Pharma Corporation – ZSAN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). To join the class...
Nov 12, 2020 09:45 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
LOS ANGELES, Nov. 12, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period").
Nov 11, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Nov 11, 2020 11:00 am ET
ZSAN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Zosano Pharma Corporation of Class Action and Encourages Shareholders to Contact the Firm
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Nov 10, 2020 04:30 pm ET
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contac
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020...
Nov 10, 2020 10:30 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
BENSALEM, Pa., Nov. 10, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period").
Nov 09, 2020 06:26 pm ET
ROSEN, A LEADING LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ZSAN
NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), of the important December 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.
Nov 08, 2020 04:45 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm –
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.
Nov 06, 2020 10:54 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Zosano Pharma Corporation and Certain Officers - ZSAN
NEW YORK, Nov. 6, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers.  The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-07850, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Zosano securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"), seeking to pursue claims against the Defendants
Nov 06, 2020 11:30 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
Law Offices of Howard G. Smith reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020
Nov 05, 2020 11:00 am ET
ZSAN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Zosano Pharma Corporation of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers, on behalf of...
Nov 04, 2020 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zosano Pharma Corporation (NASDAQ: ZSAN), Celsion Corporation (NASDAQ: CLSN),...
Nov 04, 2020 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 28, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ:
Nov 03, 2020 11:30 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zosano Pharma Corporation (ZSAN) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). Zosano investors have until December 28, 2020
Nov 03, 2020 10:00 am ET
ZSAN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Zosano Pharma Corporation of Class Action and Encourages Shareholders to Contact the Firm
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Zosano securities between February 13, 2017 and September 30, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/zsan.                
Nov 02, 2020 06:51 pm ET
Shareholder Alert: Robbins LLP Announces Zosano Pharma Corporation (ZSAN) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Zosano Pharma Corporation (NASDAQ: ZSAN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between February 13, 2017 and September 30, 2020. Zosano Pharma is a c
Nov 02, 2020 09:45 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zosano Pharma Corporation (“Zosano” or “the Company”) (NASDAQ:
Oct 30, 2020 08:00 pm ET
ZOSANO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zosano Pharma Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Zosano Pharma Corp. (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020 (the “Class Period”). Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 30, 2020 07:51 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zosano Pharma Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zosano Pharma Corporation (“Zosano” or “the Company”) (NASDAQ:
Oct 30, 2020 06:50 pm ET
ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation – ZSAN
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.
Oct 30, 2020 11:00 am ET
ZSAN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Zosano Pharma Corporation
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Carr v. Zosano Pharma Corporation, et al., (Case No. 3:20-cv-07625) on behalf of persons and entities that purchased or otherwise acquired Zosano Pharma C
Oct 30, 2020 08:43 am ET
Class Action Filed Against Zosano Pharma – ZSAN Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. continues its investigation of potential securities claims on behalf of investors of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) to determine whether the Company engaged in securities fraud or other...
Oct 29, 2020 07:51 pm ET
ZSAN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Zosano Pharma Corporation
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Carr v. Zosano Pharma Corporation, et al., (Case No. 3:20-cv-07625) on behalf of persons and entities that purchased or otherwise acquired Zosano Pharma
Oct 23, 2020 08:00 pm ET
ZOSANO PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zosano Pharma Corp. on Behalf of Zosano Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zosano Pharma Corp. (NASDAQ: ZSAN) on behalf of Zosano stockholders. Our investigation concerns whether Zosano has violated...
Oct 23, 2020 12:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ:
Oct 22, 2020 03:33 pm ET
Zosano Pharma Investors Who Have Suffered Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Zosano Pharma Corporation (NASDAQ: ZSAN) to determine whether the Company engaged in securities fraud or other unlawful business practices. Zosano...
Oct 22, 2020 12:47 pm ET
SHAREHOLDER ALERT: Zosano Pharma Corp. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm
On September 30, 2020, Zosano Pharma Corp. (NASDAQ: ZSAN) stunned the market when it announced that it had received “a discipline review letter (DRL) from the U.S. Food and Drug Administration” in connection with Zosano’s new drug application for...
Oct 22, 2020 11:30 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) investors concerning the Company’s possible violations of federal securities laws.
Oct 21, 2020 06:46 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zosano Pharma Corporation (ZSAN) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ:
Oct 21, 2020 08:30 am ET
Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, announced today that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™...
Sep 30, 2020 05:40 pm ET
Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™ (zolmitriptan...
Sep 09, 2020 08:30 am ET
Zosano Pharma to Present at the Cantor Virtual Global Healthcare Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the Cantor Virtual Global Healthcare Conference on...
Sep 03, 2020 08:00 am ET
Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment...
Sep 01, 2020 09:00 am ET
Zosano Announces Pricing of Public Offering of Common Stock
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 15,937,130 shares of its common stock for gross proceeds of approximately $20.8 million, before...
Aug 31, 2020 04:05 pm ET
Zosano Pharma Announces Proposed Public Offering of Common Stock
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered...
Aug 18, 2020 08:30 am ET
Zosano Pharma Announces Agreement to Collaborate with Mitsubishi Tanabe Pharma Corporation
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company that develops and...
Aug 06, 2020 05:00 pm ET
Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced it has partnered with EVERSANA, a leading provider of commercial services to the life science industry, to commercialize and distribute Qtrypta™ in...
Aug 06, 2020 08:00 am ET
Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020, as well as recent business highlights. “Zosano is on the cusp of potentially...
Aug 03, 2020 04:05 pm ET
Zosano Pharma to Present at the BTIG Biotechnology Conference 2020
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday,...
Jun 13, 2020 06:00 am ET
Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 Amer
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of QtryptaTM, Zosano’s lead investigational product candidate for the acute treatment of migraine, will be...
Jun 11, 2020 04:05 pm ET
Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
Zosano Pharma Corporation (Nasdaq:ZSAN) (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced a change in the format of its Annual Meeting of Stockholders (“Annual Meeting”) from in-person to virtual-only. Due to...
May 14, 2020 05:05 pm ET
Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2020, as well as recent business highlights. "This quarter was marked by a momentous...
May 01, 2020 04:35 pm ET
Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the company’s chief financial officer (CFO). Ms. Matthews, who previously served as interim CFO, will be...
Mar 13, 2020 08:00 am ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2019, as well as recent business highlights. “2019 was a transformational...
Mar 06, 2020 05:15 pm ET
Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market
Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 11,903,506 shares of...
Mar 05, 2020 08:00 am ET
Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market
Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the issuance and sale in a registered direct offering of...
Mar 04, 2020 08:00 am ET
Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta™ for the Acute Treatment of Migraine
Zosano Pharma Corporation (Nasdaq: ZSAN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Qtrypta™ for filing and substantive review. The...
Feb 12, 2020 08:20 am ET
Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and Warrants
Zosano Pharma Corporation (Nasdaq:ZSAN)  (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of (i) 10,146,154 Class A Units, each consisting...
Feb 11, 2020 04:35 pm ET
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of...
Dec 23, 2019 08:00 am ET
Zosano Announces FDA Submission of New Drug Application for Qtrypta
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the submission of a 505(b)(2) New Drug Application (“NDA”) for Qtrypta™ to the U.S. Food and Drug Administration (“FDA”) for the acute treatment of...
Nov 27, 2019 09:29 am ET
Zosano Announces Pricing of Registered Direct Offering
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with several institutional investors providing for the issuance and sale of an aggregate...
Nov 14, 2019 04:05 pm ET
Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019, as well as recent business highlights. "These next twelve months will be...
Nov 13, 2019 04:30 pm ET
Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has received minutes from pre- New Drug Application (“NDA”) meetings with the Food and Drug Administration (“FDA”) for the acute treatment...
Nov 07, 2019 09:00 am ET
Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, November 14, 2019 at 4:30 p.m. ET to discuss results for the third quarter of 2019 and...
Oct 24, 2019 09:00 am ET
Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster Headache
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling cluster headache patients in the ATAC clinical trial. This Phase 2/3 study will evaluate the efficacy of C213...
Oct 23, 2019 04:05 pm ET
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 450,000 shares of Zosano’s common stock to Steven Lo in connection with his...
Oct 08, 2019 09:00 am ET
Zosano Pharma Announces CEO Transition
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical executive, will become president and chief executive officer of Zosano effective October...
Sep 27, 2019 04:05 pm ET
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100,000 shares of Zosano’s common stock to a new employee as an inducement award....
Sep 26, 2019 09:00 am ET
Zosano Pharma to Present at the Cantor Global Healthcare Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview at the 2019 Cantor Global Healthcare...
Sep 18, 2019 08:30 am ET
Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice president of business development. “We are pleased to welcome Dushyant, who brings over...
Sep 09, 2019 08:30 am ET
Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced an oral presentation and two poster presentations of positive data from a one-year long-term safety study of Qtrypta™ for the acute treatment of...
Sep 03, 2019 09:00 am ET
Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview at the H.C. Wainwright 21st Annual Global...
Aug 23, 2019 09:00 am ET
Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company will deliver an oral presentation and two poster presentations at the 19th Congress of the International Headache Society (IHC)....
Aug 14, 2019 04:05 pm ET
Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019, as well as recent business highlights. "We have concentrated our efforts on...
Aug 14, 2019 09:00 am ET
Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2/3...
Aug 07, 2019 04:05 pm ET
Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss results for the second quarter of 2019 and...
Jul 15, 2019 06:00 am ET
Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of Migraine-ACT scores for Qtrypta™ therapy used over 6-12 months. The Migraine Assessment of Current Therapy (or Migraine-ACT)...
Jul 03, 2019 08:30 am ET
Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous...
Jul 01, 2019 04:05 pm ET
Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with the management of their migraines, following...
Jun 18, 2019 06:00 am ET
Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has completed manufacturing of site qualification batches at its commercial manufacturing site for Qtrypta, the company’s investigational...
May 14, 2019 04:05 pm ET
Zosano Pharma Reports First Quarter 2019 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2019, as well as recent business highlights. "With a number of key catalysts planned in...
May 09, 2019 09:00 am ET
Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase...
May 08, 2019 04:30 pm ET
Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and...
Apr 16, 2019 08:30 am ET
Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed trials using newly FDA-recommended...
Apr 16, 2019 07:30 am ET
New Research Coverage Highlights Franklin Resources, Corporate Office Properties Trust, Guidewire Software, Bemis, T2 Biosystems, and Zosano Pharma — Consolidated Revenues, Company Growth, and Expecta
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Franklin Resources, Inc. (NYSE:BEN), Corporate Office Properties Trust...
Apr 09, 2019 09:00 am ET
Zosano Announces Pricing of Public Offering of Common Stock
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and...
Apr 08, 2019 04:01 pm ET
Zosano Pharma Announces Proposed Public Offering of Common Stock
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered...
Mar 14, 2019 04:05 pm ET
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.
Mar 11, 2019 04:30 pm ET
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will participate in a panel titled “Drug Delivery” to be held on Monday,...
Mar 07, 2019 04:30 pm ET
Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter and...
Feb 25, 2019 07:45 am ET
Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Zosano Pharma Corporation (NASDAQ:ZSAN), Appian Corporation (NASDAQ:APPN),...
Feb 22, 2019 08:31 am ET
Thinking about buying stock in Apple, Canopy Growth Corp, Immune Design, Roku Inc or Zosano Pharma?
NEW YORK, Feb. 22, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CGC, IMDZ, ROKU, and ZSAN.
Feb 21, 2019 06:00 am ET
Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which patients treated migraine attacks over a one year...
Jan 31, 2019 08:30 am ET
Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal...
Jan 16, 2019 08:30 am ET
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of...
Dec 12, 2018 08:30 am ET
Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name Qtrypta™ for M207,...
Nov 14, 2018 04:05 pm ET
Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2018. “The Company has continued to execute upon our...
Nov 07, 2018 04:30 pm ET
Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET. At this time,...
Oct 25, 2018 09:15 am ET
Recent Analysis Shows Stellus Capital Investment, Nuance Communications, ProPetro Holding, Sanchez Energy, Granite Point Mortgage Trust, and Zosano Pharma Market Influences — Renewed Outlook, Key Driv
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Stellus Capital Investment Corporation (NYSE:SCM), Nuance...
Oct 23, 2018 08:30 am ET
Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study  
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a...
Oct 18, 2018 08:00 am ET
Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Oct 16, 2018 08:30 am ET
Zosano Appoints New Chief Financial Officer
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Oct 03, 2018 08:30 am ET
Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Sep 26, 2018 08:30 am ET
Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,...
Sep 19, 2018 08:30 am ET
Zosano Pharma Completes Manufacture of M207 Registration Batches
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied...
Sep 06, 2018 08:30 am ET
Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary...
Sep 05, 2018 08:30 am ET
Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine Trust International Symposium (MTIS)
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied...
Aug 09, 2018 04:00 pm ET
Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology called Adhesive Dermally-Applied...
Aug 02, 2018 08:30 am ET
Zosano Pharma to Host Conference Call on Second Quarter 2018 Financial Results and Provide Operational Update
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray...
Jul 17, 2018 08:30 am ET
Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan
Zosano Pharma (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied...
Jun 27, 2018 02:00 pm ET
Zosano to Present Additional Analyses from the ZOTRIP Pivotal Study on Pain Relief and Recurrence at the 2018 American Headache Society (AHS) Meeting
Zosano Pharma, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray...
Jun 20, 2018 08:30 am ET
Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied...
May 31, 2018 08:20 am ET
Market Trends Toward New Normal in ANSYS, Pearson, Qualys, H. B. Fuller, Cabot Microelectronics, and Zosano Pharma — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, Inc. (NASDAQ:ANSS), Pearson, PLC (NYSE:PSO), Qualys, Inc....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.